Norfos vaistinė - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 38,118,582 | 45,502,092 | 58,403,073 | 69,115,152 | 81,108,494 | 89,525,813 | 101,875,878 | 115,264,114 |
| Profit before tax | 4,390,768 | 5,333,319 | 7,338,660 | 8,857,051 | 9,353,099 | 8,751,317 | 9,551,848 | 10,618,065 |
| Net profit | 3,696,009 | 4,491,256 | 6,190,763 | 7,520,878 | 7,876,663 | 7,352,901 | 8,035,298 | 8,860,626 |
| Equity | 4,402,563 | 4,893,818 | 6,193,949 | 7,524,064 | 7,879,849 | 7,356,087 | 8,038,485 | 8,863,812 |
| Liabilities | 1,338,237 | 2,648,363 | 2,479,346 | 3,098,471 | 5,267,223 | 5,901,297 | 6,319,756 | 7,910,861 |
| Non-current assets | 507,710 | 587,829 | 748,042 | 1,347,685 | 1,420,537 | 1,399,340 | 1,446,125 | 1,548,513 |
| Current assets | 5,472,898 | 7,225,346 | 8,302,896 | 9,590,459 | 12,057,702 | 12,177,619 | 13,298,619 | 15,646,564 |
| Total assets | 5,980,608 | 7,813,175 | 9,050,938 | 10,938,144 | 13,478,239 | 13,576,959 | 14,744,744 | 17,195,077 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 6,591,871 | 7,444,543 | 8,526,920 |
| Social insurance contributions | - | - | - | - | - | 3,038,226 | 3,822,191 | 4,335,710 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +9.5% | +19.4% | +28.4% | +18.3% | +17.4% | +10.4% | +13.8% | +13.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 61.8% | 57.5% | 68.4% | 68.8% | 58.4% | 54.2% | 54.5% | 51.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 84.0% | 91.8% | 99.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 9.7% | 9.9% | 10.6% | 10.9% | 9.7% | 8.2% | 7.9% | 7.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 11.5% | 11.7% | 12.6% | 12.8% | 11.5% | 9.8% | 9.4% | 9.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | 0.5 | 0.4 | 0.4 | 0.7 | 0.8 | 0.8 | 0.9 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 99,722 | 112,932 | 131,366 | 146,275 | 158,984 | 174,685 | 191,346 | 211,397 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Norfos vaistinė - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-02-18 | 2026-02-22 | 0.30 |
| 2026-01-22 | 2026-02-12 | 0.30 |
| 2025-10-26 | 2025-11-02 | 0.15 |
| 2025-06-30 | 2025-07-13 | 60.43 |
| 2025-04-16 | 2025-04-17 | 282.51 |
| 2025-02-18 | 2025-02-20 | 0.17 |
| 2025-02-11 | 2025-02-13 | 3.82 |
| 2025-02-10 | 2025-02-10 | 0.17 |
| 2025-02-04 | 2025-02-09 | 3.82 |
| 2025-01-22 | 2025-02-03 | 0.17 |
| 2024-12-17 | 2024-12-17 | 222.99 |
| 2023-12-18 | 2023-12-18 | 0.41 |
Norfos vaistinė - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Norfos vaistine, UAB (code 300536823) is a private limited liability company engaged in the retail sale of pharmaceutical products. In 2025, the company generated revenue of €115.26M and net profit of €8.86M, compared with €101.88M revenue and €8.04M net profit in 2024 and €89.53M revenue and €7.35M net profit in 2023. This shows a steady upward trend over the last three years, with revenue up 13.1% year on year in 2025 and 28.8% higher than two years earlier. Profitability remained solid, although the net profit margin eased slightly from 8.2% in 2023 to 7.9% in 2024 and 7.7% in 2025. At the end of 2025, total assets stood at €17.20M, equity at €8.86M and liabilities at €7.91M. The company reported a debt-to-equity ratio of 0.89 and an asset turnover of 6.70x. Return on equity was 100.0% and return on assets 51.5%. Revenue per employee was €211.5K, indicating strong productivity.